Jane S Paulsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2865866/publications.pdf

Version: 2024-02-01

301 papers

25,027 citations

75 h-index 9865 146 g-index

308 all docs 308 docs citations

308 times ranked 18237 citing authors

#	Article	IF	CITATIONS
1	Traumatic Brain Injury in Children and Adolescents: Psychiatric Disorders 24 Years Later. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 60-67.	0.9	9
2	Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. American Journal of Human Genetics, 2022, 109, 885-899.	2.6	29
3	Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience, 2022, 25, 446-457.	7.1	31
4	Human brain extraction with deep learning. , 2022, , .		3
5	Predicting an optimal composite outcome variable for Huntington's disease clinical trials. Journal of Applied Statistics, 2021, 48, 1339-1348.	0.6	1
6	Longitudinal subcortical segmentation with deep learning. , 2021, 11596, .		2
7	MRI subcortical segmentation in neurodegeneration with cascaded 3D CNNs. , 2021, $11596,\ldots$		6
8	Tracking Huntington $\hat{E}^{1}\!\!/\!\!4$ s Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers. Movement Disorders, 2021, 36, 2282-2292.	2.2	10
9	Long-Term Psychiatric Outcomes in Adults with History of Pediatric Traumatic Brain Injury. Journal of Neurotrauma, 2021, 38, 1515-1525.	1.7	10
10	Meaning and purpose in Huntington's disease: a longitudinal study of its impact on quality of life. Annals of Clinical and Translational Neurology, 2021, 8, 1668-1679.	1.7	8
11	Mild Cognitive Impairment as an Early Landmark in Huntington's Disease. Frontiers in Neurology, 2021, 12, 678652.	1.1	6
12	A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington's Disease. Frontiers in Big Data, 2021, 4, 662200.	1.8	2
13	Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. Neurology: Genetics, 2021, 7, e617.	0.9	20
14	Moderate Intensity Exercise in Pre-manifest Huntington's Disease: Results of a 6 months Trial, 2021, 2, 6-36.		0
15	Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD). Quality of Life Research, 2020, 29, 1393-1403.	1.5	8
16	Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease. Biological Psychiatry, 2020, 87, 857-865.	0.7	29
17	Tensor-Based Grading: A Novel Patch-Based Grading Approach for the Analysis Of Deformation Fields in Huntington's Disease., 2020, 2020, 1091-1095.		2
18	Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD). Quality of Life Research, 2020, 29, 3419-3439.	1.5	9

#	Article	IF	Citations
19	Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease. Annals of Neurology, 2020, 87, 751-762.	2.8	22
20	Understanding domains that influence perceived stigma in individuals with Huntington disease Rehabilitation Psychology, 2020, 65, 113-121.	0.7	4
21	Time-varying Hazards Model for Incorporating Irregularly Measured, High-Dimensional Biomarkers. Statistica Sinica, 2020, 30, 1605-1632.	0.2	0
22	Generalizing MRI Subcortical Segmentation to Neurodegeneration. Lecture Notes in Computer Science, 2020, , 139-147.	1.0	3
23	Patch-Based Abnormality Maps for Improved Deep Learning-Based Classification of Huntington's Disease. Lecture Notes in Computer Science, 2020, 12267, 636-645.	1.0	1
24	CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset. Cell, 2019, 178, 887-900.e14.	13.5	301
25	How different aspects of motor dysfunction influence dayâ€toâ€day function in huntington's disease. Movement Disorders, 2019, 34, 1910-1914.	2.2	3
26	Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease. Journal of Huntington's Disease, 2019, 8, 467-482.	0.9	17
27	Antisense oligonucleotides might change the therapeutic landscape for Huntington's disease. Lancet Neurology, The, 2019, 18, 911-912.	4.9	1
28	End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and EndÂofÂLife Planning. Journal of Neurology, 2019, 266, 2406-2422.	1.8	9
29	Positive Affect and Well-Being in Huntington's Disease Moderates the Association Between Functional Impairment and HRQOL Outcomes. Journal of Huntington's Disease, 2019, 8, 221-232.	0.9	2
30	Concurrent Cross-Sectional and Longitudinal Analyses of Multivariate White Matter Profiles and Clinical Functioning in Pre-Diagnosis Huntington Disease. Journal of Huntington's Disease, 2019, 8, 199-219.	0.9	1
31	Apathy Is Related to Cognitive Control and Striatum Volumes in Prodromal Huntington's Disease. Journal of the International Neuropsychological Society, 2019, 25, 462-469.	1.2	13
32	Sample enrichment for clinical trials to show delay of onset in huntington disease. Movement Disorders, 2019, 34, 274-280.	2.2	10
33	Dynamic functional network connectivity in Huntington's disease and its associations with motor and cognitive measures. Human Brain Mapping, 2019, 40, 1955-1968.	1.9	46
34	Regional subcortical shape analysis in premanifest Huntington's disease. Human Brain Mapping, 2019, 40, 1419-1433.	1.9	20
35	Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. Journal of Neurology, 2018, 265, 1443-1453.	1.8	7
36	Rating scales for cognition in Huntington's disease: Critique and recommendations. Movement Disorders, 2018, 33, 187-195.	2.2	38

#	Article	IF	Citations
37	MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. Neurology, 2018, 90, e264-e272.	1.5	65
38	Whole-Brain Connectivity in a Large Study of Huntington's Disease Gene Mutation Carriers and Healthy Controls. Brain Connectivity, 2018, 8, 166-178.	0.8	39
39	Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 194-201.	0.9	42
40	Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures. Quality of Life Research, 2018, 27, 811-822.	1.5	12
41	Understanding the need for assistance with survey completion in people with Huntington disease. Quality of Life Research, 2018, 27, 801-810.	1.5	1
42	Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes. Journal of Huntington's Disease, 2018, 7, 337-344.	0.9	4
43	Genetic load determines atrophy in hand corticoâ€striatal pathways in presymptomatic Huntington's disease. Human Brain Mapping, 2018, 39, 3871-3883.	1.9	13
44	Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease. Journal of Huntington's Disease, 2018, 7, 239-249.	0.9	18
45	Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease. Frontiers in Neurology, 2018, 9, 190.	1.1	4
46	A Fully-Automated Subcortical and Ventricular Shape Generation Pipeline Preserving Smoothness and Anatomical Topology. Frontiers in Neuroscience, 2018, 12, 321.	1.4	14
47	High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington's Disease. Brain Sciences, 2018, 8, 116.	1.1	3
48	Genetic Modification of Huntington Disease Acts Early in the Prediagnosis Phase. American Journal of Human Genetics, 2018, 103, 349-357.	2.6	30
49	Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?. Quality of Life Research, 2018, 27, 2541-2555.	1.5	10
50	Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures Psychological Assessment, 2018, 30, 450-458.	1.2	9
51	Analysis of longitudinal censored semicontinuous data with application to the study of executive dysfunction: The Towers Task. Statistical Methods in Medical Research, 2017, 26, 865-879.	0.7	1
52	Substance abuse may hasten motor onset of Huntington disease. Neurology, 2017, 88, 909-915.	1.5	30
53	Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington's Disease Phenotype. Journal of the International Neuropsychological Society, 2017, 23, 159-170.	1.2	20
54	Data quality assurance and control in cognitive research: Lessons learned from the PREDICTâ€HD study. International Journal of Methods in Psychiatric Research, 2017, 26, .	1.1	4

#	Article	IF	CITATIONS
55	Validation of a prognostic index for Huntington's disease. Movement Disorders, 2017, 32, 256-263.	2.2	42
56	Dynamic Prediction of Motor Diagnosis inÂHuntington's Disease Using a Joint Modeling Approach. Journal of Huntington's Disease, 2017, 6, 127-137.	0.9	10
57	Longitudinal diffusion changes in prodromal and early <scp>HD</scp> : Evidence of whiteâ€matter tract deterioration. Human Brain Mapping, 2017, 38, 1460-1477.	1.9	45
58	Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease. Journal of Huntington's Disease, 2017, 6, 201-215.	0.9	1
59	Subject-specific longitudinal shape analysis by coupling spatiotemporal shape modeling with medial analysis. Proceedings of SPIE, 2017, 10133, .	0.8	1
60	Mapping the order and pattern of brain structural MRI changes using changeâ€point analysis in premanifest Huntington's disease. Human Brain Mapping, 2017, 38, 5035-5050.	1.9	28
61	Cognitive and behavioral changes in Huntington disease before diagnosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 69-91.	1.0	58
62	Patterns of Co-Occurring Gray Matter Concentration Loss across the Huntington Disease Prodrome. Frontiers in Neurology, 2016, 7, 147.	1.1	26
63	An Open-Source Label Atlas Correction Tool and Preliminary Results on Huntingtons Disease Whole-Brain MRI Atlases. Frontiers in Neuroinformatics, 2016, 10, 29.	1.3	8
64	I35â€Substance abuse leads to earlier age of onset of huntington's disease: an epidemiological study of the Enroll-HD database. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A71.1-A71.	0.9	0
65	Longitudinal Changes in the Motor Learning-Related Brain Activation Response in Presymptomatic Huntington's Disease. PLoS ONE, 2016, 11, e0154742.	1.1	5
66	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. JAMA - Journal of the American Medical Association, 2016, 316, 40.	3.8	327
67	New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). Quality of Life Research, 2016, 25, 2403-2415.	1.5	27
68	Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD. Journal of Huntington's Disease, 2016, 5, 357-368.	0.9	6
69	Efficient and Extensible Workflow: Reliable Whole Brain Segmentation for Large-Scale, Multi-center Longitudinal Human MRI Analysis Using High Performance/Throughput Computing Resources. Lecture Notes in Computer Science, 2016, , 54-61.	1.0	6
70	Linking white matter and deep gray matter alterations in premanifest Huntington disease. NeuroImage: Clinical, 2016, 11, 450-460.	1.4	58
71	HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Quality of Life Research, 2016, 25, 2441-2455.	1.5	39
72	Crossâ€sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease. Movement Disorders, 2016, 31, 1664-1675.	2.2	33

#	Article	IF	Citations
73	Tissue classification of large-scale multi-site MR data using fuzzy k-nearest neighbor method. Proceedings of SPIE, 2016, , .	0.8	6
74	Cognitive changes associated with switching to frequent nocturnal hemodialysis or renal transplantation. BMC Nephrology, 2016, 17, 12.	0.8	27
75	The impact of oculomotor functioning on neuropsychological performance in Huntington disease. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 217-226.	0.8	3
76	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). JAMA Neurology, 2016, 73, 102.	4.5	38
77	Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data. American Journal of Psychiatry, 2016, 173, 184-192.	4.0	106
78	Is There an Association of Physical Activity with Brain Volume, Behavior, and Day-to-day Functioning? A Cross Sectional Design in Prodromal and Early Huntington Disease. PLOS Currents, 2016, 8, .	1.4	10
79	Bayesian covariate selection in mixed-effects models for longitudinal shape analysis. , 2016, 2016, 656-659.		2
80	Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICTâ€HD. Movement Disorders, 2015, 30, 1664-1672.	2.2	38
81	Everyday cognition in prodromal Huntington disease Neuropsychology, 2015, 29, 255-267.	1.0	18
82	Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease Neuropsychology, 2015, 29, 949-960.	1.0	13
83	Practice Effects and Stability of Neuropsychological and UHDRS Tests Over Short Retest Intervals in Huntington Disease. Journal of Huntington's Disease, 2015, 4, 251-260.	0.9	2
84	T1ϕimaging in premanifest Huntington disease reveals changes associated with disease progression. Movement Disorders, 2015, 30, 1107-1114.	2.2	16
85	Prefrontal cortex white matter tracts in prodromal <scp>H</scp> untington disease. Human Brain Mapping, 2015, 36, 3717-3732.	1.9	45
86	Preliminary analysis using multi-atlas labeling algorithms for tracing longitudinal change. Frontiers in Neuroscience, 2015, 9, 242.	1.4	28
87	Factors influencing the clinical expression of intermediate CAG repeat length mutations of the Huntington's disease gene. Journal of Neurology, 2015, 262, 277-284.	1.8	7
88	Validity of the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD). Quality of Life Research, 2015, 24, 1963-1971.	1.5	51
89	Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden. Journal of the International Neuropsychological Society, 2015, 21, 8-21.	1.2	8
90	Network topology and functional connectivity disturbances precede the onset of Huntington's disease. Brain, 2015, 138, 2332-2346.	3.7	99

#	Article	IF	Citations
91	Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell, 2015, 162, 516-526.	13.5	514
92	Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease. European Journal of Human Genetics, 2015, 23, 1584-1587.	1.4	16
93	Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin. Molecular Psychiatry, 2015, 20, 1286-1293.	4.1	45
94	Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. Journal of Neurology, 2015, 262, 2691-2698.	1.8	17
95	Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. Frontiers in Aging Neuroscience, 2014, 6, 78.	1.7	177
96	Deep learning for neuroimaging: a validation study. Frontiers in Neuroscience, 2014, 8, 229.	1.4	441
97	The power-proportion method for intracranial volume correction in volumetric imaging analysis. Frontiers in Neuroscience, 2014, 8, 356.	1.4	35
98	Results of the citalopram to enhance cognition in Huntington disease trial. Movement Disorders, 2014, 29, 401-405.	2.2	45
99	WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease. European Journal of Human Genetics, 2014, 22, 958-963.	1.4	33
100	Movement sequencing in Huntington disease. World Journal of Biological Psychiatry, 2014, 15, 459-471.	1.3	14
101	Functional Connectivity of Primary Motor Cortex Is Dependent on Genetic Burden in Prodromal Huntington Disease. Brain Connectivity, 2014, 4, 535-546.	0.8	28
102	Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease. Brain and Behavior, 2014, 4, 29-40.	1.0	55
103	Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Human Brain Mapping, 2014, 35, 792-809.	1.9	58
104	Diffusion weighted imaging of prefrontal cortex in prodromal huntington's disease. Human Brain Mapping, 2014, 35, 1562-1573.	1.9	49
105	Diagnostic Criteria for Vascular Cognitive Disorders. Alzheimer Disease and Associated Disorders, 2014, 28, 206-218.	0.6	529
106	Preliminary Study of the Association of White-Matter Metabolite Concentrations With Disease Severity in Patients With Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2014, 26, 101-104.	0.9	1
107	Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 2014, 10, 204-216.	4.9	873
108	Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurology, The, 2014, 13, 1193-1201.	4.9	202

#	Article	IF	Citations
109	Tracking motor impairments in the progression of Huntington's disease. Movement Disorders, 2014, 29, 311-319.	2.2	49
110	Classifying neurocognitive disorders: the DSM-5 approach. Nature Reviews Neurology, 2014, 10, 634-642.	4.9	589
111	Onset of Huntington's disease: Can it be purely cognitive?. Movement Disorders, 2014, 29, 1342-1350.	2.2	53
112	Disruption of response inhibition circuits in prodromal Huntington disease. Cortex, 2014, 58, 72-85.	1.1	30
113	Does Interval Between Screening and Baseline Matter in HD Cognitive Clinical Trials?. Journal of Huntington's Disease, 2014, 3, 139-144.	0.9	1
114	Diffeomorphic Shape Trajectories for Improved Longitudinal Segmentation and Statistics. Lecture Notes in Computer Science, 2014, 17, 49-56.	1.0	10
115	Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. Journal of Psychiatric Research, 2013, 47, 1423-1431.	1.5	54
116	A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Progress in Neurobiology, 2013, 110, 2-28.	2.8	128
117	Strategies Used by Teens Growing Up in Families With Huntington Disease. Journal of Pediatric Nursing, 2013, 28, 464-469.	0.7	12
118	Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiology of Disease, 2013, 55, 37-43.	2.1	80
119	Managing juvenile Huntington's disease. Neurodegenerative Disease Management, 2013, 3, 267-276.	1.2	78
120	Cognitive decline in prodromal Huntington Disease: implications for clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1233-1239.	0.9	93
121	Unawareness of motor phenoconversion in Huntington disease. Neurology, 2013, 81, 1141-1147.	1.5	32
122	Measuring Executive Dysfunction Longitudinally and in Relation to Genetic Burden, Brain Volumetrics, and Depression in Prodromal Huntington Disease. Archives of Clinical Neuropsychology, 2013, 28, 156-168.	0.3	22
123	Psychological well-being in persons affected by Huntington's disease: A comparison of at-risk, prodromal, and symptomatic groups. Journal of Health Psychology, 2013, 18, 408-418.	1.3	11
124	Metabolic network as a progression biomarker of premanifest Huntington's disease. Journal of Clinical Investigation, 2013, 123, 4076-4088.	3.9	91
125	Symptom Validity Test Performance in the Huntington Disease Clinic. Archives of Clinical Neuropsychology, 2013, 28, 135-143.	0.3	17
126	Perception, Experience, and Response to Genetic Discrimination in Huntington's Disease: The Australian Results of the International RESPOND-HD Study. Genetic Testing and Molecular Biomarkers, 2013, 17, 115-121.	0.3	21

#	Article	lF	CITATIONS
127	Cognitive Reserve and Brain Reserve in Prodromal Huntington's Disease. Journal of the International Neuropsychological Society, 2013, 19, 739-750.	1.2	48
128	Regional Atrophy Associated with Cognitive and Motor Function in Prodromal Huntington Disease. Journal of Huntington's Disease, 2013, 2, 477-489.	0.9	58
129	Bias in Estimation of a Mixture of Normal Distributions. Journal of Biometrics & Biostatistics, 2013, 04,	4.0	4
130	Refining the diagnosis of Huntington disease: the PREDICT-HD study. Frontiers in Aging Neuroscience, 2013, 5, 12.	1.7	66
131	Cognitive domains that predict time to diagnosis in prodromal Huntington disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 612-619.	0.9	90
132	Establishing a clinical trial battery for Huntington disease. Nature Reviews Neurology, 2012, 8, 250-251.	4.9	5
133	MultiCenter Reliability of Diffusion Tensor Imaging. Brain Connectivity, 2012, 2, 345-355.	0.8	77
134	Development of the HD-Teen Inventory. Clinical Nursing Research, 2012, 21, 213-223.	0.7	7
135	Development of the Huntington Disease Work Function Scale. Journal of Occupational and Environmental Medicine, 2012, 54, 1300-1308.	0.9	9
136	Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease Neuropsychology, 2012, 26, 664-669.	1.0	43
137	Couples' Coping in Prodromal Huntington Disease: A Mixed Methods Study. Journal of Genetic Counseling, 2012, 21, 662-670.	0.9	16
138	Perceived stress in prodromal Huntington disease. Psychology and Health, 2012, 27, 196-209.	1.2	22
139	Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Research, 2012, 196, 309-314.	1.7	22
140	Measures of growth in children at risk for Huntington disease. Neurology, 2012, 79, 668-674.	1.5	69
141	Striatal Volume Contributes to the Prediction of Onset of Huntington Disease in Incident Cases. Biological Psychiatry, 2012, 71, 822-828.	0.7	95
142	Clinical predictors of driving status in Huntington's disease. Movement Disorders, 2012, 27, 1146-1152.	2.2	22
143	Family carer personal concerns in Huntington disease. Journal of Advanced Nursing, 2012, 68, 137-146.	1.5	35
144	80HdG as a marker for Huntington disease progression. Neurobiology of Disease, 2012, 46, 625-634.	2.1	58

#	Article	lF	CITATIONS
145	Behavior and Personality Disturbances. , 2012, , 73-91.		1
146	Neuropsychology., 2012,, 570-586.		0
147	Neurocognitive signs in prodromal Huntington disease Neuropsychology, 2011, 25, 1-14.	1.0	341
148	The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 567-579.	0.8	52
149	Practice Effects Predict Cognitive Outcome in Amnestic Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2011, 19, 932-939.	0.6	98
150	Fully automated analysis using BRAINS: AutoWorkup. NeuroImage, 2011, 54, 328-336.	2.1	76
151	Classification of Neurocognitive Disorders in DSM-5: A Work in Progress. American Journal of Geriatric Psychiatry, 2011, 19, 205-210.	0.6	91
152	Suicidal ideation in Huntington disease: The role of comorbidity. Psychiatry Research, 2011, 188, 372-376.	1.7	82
153	Quality of Life in Prodromal HD: Qualitative Analyses of Discourse from Participants and Companions. Neurology Research International, 2011, 2011, 1-7.	0.5	4
154	Cognitive Impairment in Huntington Disease: Diagnosis and Treatment. Current Neurology and Neuroscience Reports, 2011, 11, 474-483.	2.0	282
155	An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Movement Disorders, 2011, 26, 877-884.	2.2	34
156	Factors associated with experiences of genetic discrimination among individuals at risk for huntington disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 19-27.	1.1	14
157	Indexing disease progression at study entry with individuals atâ€risk for Huntington disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 751-763.	1.1	193
158	The Neuropsychological Course of Acute Delirium in Adult Hematopoietic Stem Cell Transplantation Patients. Archives of Clinical Neuropsychology, 2011, 26, 98-109.	0.3	15
159	Estimating Premorbid Functioning in Huntington's Disease: The Relationship between Disease Progression and the Wide Range Achievement Test Reading Subtest. Archives of Clinical Neuropsychology, 2011, 26, 59-66.	0.3	16
160	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain, 2011, 134, 137-142.	3.7	118
161	Suicidal Behavior in Prodromal Huntington Disease. Neurodegenerative Diseases, 2011, 8, 483-490.	0.8	48
162	Longitudinal change in regional brain volumes in prodromal Huntington disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 405-410.	0.9	220

#	Article	IF	CITATIONS
163	Depression in the early stages of Huntington disease. Neurodegenerative Disease Management, 2011, 1, 407-414.	1.2	74
164	Estimating Premorbid IQ in the Prodromal Phase of a Neurodegenerative Disease. Clinical Neuropsychologist, 2011, 25, 757-777.	1.5	15
165	Association between Age and Striatal Volume Stratified by CAG Repeat Length in Prodromal Huntington Disease. PLOS Currents, 2011, 3, RRN1235.	1.4	25
166	Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: "Anger and Irritability" and "Obsessions and Compulsions". PLOS Currents, 2011, 3, RRN1241.	1.4	6
167	Assessment of Depression, Anxiety and Apathy in Prodromal and Early Huntington Disease. PLOS Currents, 2011, 3, RRN1242.	1.4	14
168	Assessment of Motor Symptoms and Functional Impact in Prodromal and Early Huntington Disease. PLOS Currents, 2011, 2, RRN1244.	1.4	10
169	Assessment of Cognitive Symptoms in Prodromal and Early Huntington Disease. PLOS Currents, 2011, 3, RRN1250.	1.4	13
170	Self Reports of Day-to-Day Function in a Small Cohort of People with Prodromal and Early HD. PLOS Currents, 2011, 3, RRN1254.	1.4	13
171	Assessment of Day-to-Day Functioning in Prodromal and Early Huntington Disease. PLOS Currents, 2011, 3, RRN1262.	1.4	12
172	Self-paced timing detects and tracks change in prodromal Huntington disease Neuropsychology, 2010, 24, 435-442.	1.0	79
173	Couples' Attributions for Work Function Changes in Prodromal Huntington Disease. Journal of Genetic Counseling, 2010, 19, 343-352.	0.9	14
174	Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease, 2010, 40, 531-543.	2.1	74
175	Cerebral cortex structure in prodromal Huntington disease. Neurobiology of Disease, 2010, 40, 544-554.	2.1	142
176	CAGâ€repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 397-408.	1.1	289
177	Perception, experience, and response to genetic discrimination in Huntington disease: The international RESPONDâ€HD study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1081-1093.	1.1	42
178	In their own words: Reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPONDâ€HD study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1150-1159.	1.1	33
179	Challenges assessing clinical endpoints in early Huntington disease. Movement Disorders, 2010, 25, 2595-2603.	2.2	65
180	Huntington disease: families' experiences of healthcare services. Journal of Advanced Nursing, 2010, 66, 500-510.	1.5	34

#	Article	IF	CITATIONS
181	Predicting Cognitive Change in Older Adults: The Relative Contribution of Practice Effects. Archives of Clinical Neuropsychology, 2010, 25, 81-88.	0.3	52
182	Early detection of Huntington's disease. Future Neurology, 2010, 5, 85-104.	0.9	80
183	Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 573-578.	0.8	38
184	Development of the Huntington Disease Family Concerns and Strategies Survey From Focus Group Data. Journal of Nursing Measurement, 2010, 18, 83-99.	0.2	15
185	Predicting cognitive change within domains. Clinical Neuropsychologist, 2010, 24, 779-792.	1.5	6
186	"Frontal―Behaviors Before the Diagnosis of Huntington's Disease and Their Relationship to Markers of Disease Progression: Evidence of Early Lack of Awareness. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 196-207.	0.9	147
187	Practice Effects and Outcome of Cognitive Training: Preliminary Evidence from a Memory Training Course. American Journal of Geriatric Psychiatry, 2010, 18, 91.	0.6	37
188	Cognitive deficits in Huntington's disease on the Repeatable Battery for the Assessment of Neuropsychological Status. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 231-238.	0.8	42
189	Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Research Bulletin, 2010, 82, 201-207.	1.4	214
190	Earliest functional declines in Huntington disease. Psychiatry Research, 2010, 178, 414-418.	1.7	128
191	Comorbidities of Obsessive and Compulsive Symptoms in Huntington's Disease. Journal of Nervous and Mental Disease, 2010, 198, 334-338.	0.5	33
192	Personal Factors Associated with Reported Benefits of Huntington Disease Family History or Genetic Testing. Genetic Testing and Molecular Biomarkers, 2010, 14, 629-636.	0.3	25
193	Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ: British Medical Journal, 2009, 338, b2175-b2175.	2.4	98
194	Extending MCI beyond Alzheimer disease. Neurology, 2009, 72, 1116-1117.	1.5	7
195	Biomarkers to predict and track diseases. Lancet Neurology, The, 2009, 8, 776-777.	4.9	9
196	Motor abnormalities in premanifest persons with Huntington's disease: The PREDICTâ€HD study. Movement Disorders, 2009, 24, 1763-1772.	2.2	128
197	Diffusion Tensor Imaging in Preclinical Huntington's Disease. Brain Imaging and Behavior, 2009, 3, 77-84.	1.1	41
198	The emotional experiences of family carers in Huntington disease. Journal of Advanced Nursing, 2009, 65, 789-798.	1.5	63

#	Article	IF	CITATIONS
199	Functional imaging in Huntington's disease. Experimental Neurology, 2009, 216, 272-277.	2.0	93
200	Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease. Journal of Clinical Psychopharmacology, 2009, 29, 484-487.	0.7	45
201	Experiences of Teens Living in the Shadow of Huntington Disease. Journal of Genetic Counseling, 2008, 17, 327-335.	0.9	43
202	Patient and caregiver quality of life in Huntington's disease. Movement Disorders, 2008, 23, 721-726.	2.2	95
203	Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 320-325.	1.1	42
204	Neurocognitive deficits related to poor decision making in people behind bars. Psychonomic Bulletin and Review, 2008, 15, 44-51.	1.4	75
205	Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. European Journal of Human Genetics, 2008, 16, 279-289.	1.4	57
206	Neural bases of dysphoria in early Huntington's disease. Psychiatry Research - Neuroimaging, 2008, 162, 73-87.	0.9	43
207	Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 874-880.	0.9	696
208	"Preâ€symptomatic―Huntington's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 589-598.	1.0	12
209	Stability of Neuropsychological Performance in Anorexia Nervosa. Annals of Clinical Psychiatry, 2008, 20, 9-13.	0.6	17
210	Risperidone and the Treatment of Psychiatric, Motor, and Cognitive Symptoms in Huntington's Disease. Annals of Clinical Psychiatry, 2008, 20, 1-3.	0.6	62
211	Short-term practice effects in amnestic mild cognitive impairment: implications for diagnosis and treatment. International Psychogeriatrics, 2008, 20, 986-99.	0.6	69
212	Obsessive and Compulsive Symptoms in Prediagnosed Huntington's Disease. Journal of Clinical Psychiatry, 2008, 69, 1758-1765.	1.1	61
213	Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 365-376.	0.8	122
214	Predictors of diagnosis in Huntington disease. Neurology, 2007, 68, 1710-1717.	1.5	42
215	Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain, 2007, 130, 1732-1744.	3.7	181
216	Morphology of the Cerebral Cortex in Preclinical Huntington's Disease. American Journal of Psychiatry, 2007, 164, 1428-1434.	4.0	78

#	Article	IF	Citations
217	Neuropsychological Performance Is Associated With Vascular Function in Patients With Atherosclerotic Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 141-146.	1.1	26
218	Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain, 2007, 130, 2858-2867.	3.7	177
219	Caregiver burden in Huntington's disease Rehabilitation Psychology, 2007, 52, 311-318.	0.7	40
220	Neuropsychological and psychiatric functioning pre- and posthematopoietic stem cell transplantation in adult cancer patients: A preliminary study. Journal of the International Neuropsychological Society, 2007, 13, 172-7.	1.2	30
221	fMRI detection of early neural dysfunction in preclinical Huntington's disease. Journal of the International Neuropsychological Society, 2007, 13, 758-69.	1.2	99
222	Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. Journal of the International Neuropsychological Society, 2007, 13, 539-43.	1.2	87
223	Practice effects in the prediction of long-term cognitive outcome in three patient samples: A novel prognostic index. Archives of Clinical Neuropsychology, 2007, 22, 15-24.	0.3	146
224	Probability of Obsessive and Compulsive Symptoms in Huntington's Disease. Biological Psychiatry, 2007, 61, 415-418.	0.7	52
225	Psychiatric Symptoms in Huntington's Disease before Diagnosis: The Predict-HD Study. Biological Psychiatry, 2007, 62, 1341-1346.	0.7	363
226	"No one else sees the difference: â€family members' perceptions of changes in persons with preclinical Huntington disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 636-641.	1.1	28
227	Managing genetic discrimination: Strategies used by individuals found to have the Huntington disease mutation. Clinical Genetics, 2007, 71, 220-231.	1.0	33
228	Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia, 2007, 45, 1767-1776.	0.7	122
229	Evaluation of the GTRACT diffusion tensor tractography algorithm: A validation and reliability study. Neurolmage, 2006, 31, 1075-1085.	2.1	53
230	Brain Structure in Preclinical Huntington's Disease. Biological Psychiatry, 2006, 59, 57-63.	0.7	208
231	Prism adaptation in schizophrenia. Brain and Cognition, 2006, 61, 235-242.	0.8	29
232	Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study. BMC Medical Genetics, 2006, 7, 71.	2.1	72
233	Preclinical Huntington's disease: Compensatory brain responses during learning. Annals of Neurology, 2006, 59, 53-59.	2.8	106
234	Preparing for Preventive Clinical Trials. Archives of Neurology, 2006, 63, 883.	4.9	292

#	Article	IF	Citations
235	Traumatic Brain Injury in Children and Adolescents: Academic and Intellectual Outcomes Following Injury. Exceptionality, 2006, 14, 125-140.	1.1	24
236	White Matter Volume and Cognitive Dysfunction in Early Huntington's Disease. Cognitive and Behavioral Neurology, 2005, 18, 102-107.	0.5	99
237	Interrater agreement in the assessment of motor manifestations of Huntington's disease. Movement Disorders, 2005, 20, 293-297.	2.2	83
238	Critical Periods of Suicide Risk in Huntington's Disease. American Journal of Psychiatry, 2005, 162, 725-731.	4.0	199
239	Depression and Stages of Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2005, 17, 496-502.	0.9	213
240	Regression-based formulas for predicting change in RBANS subtests with older adults. Archives of Clinical Neuropsychology, 2005, 20, 281-290.	0.3	55
241	Cognitive changes in Huntington's disease. Advances in Neurology, 2005, 96, 209-25.	0.8	28
242	Blood Vessel Function and Cognition in Elderly Patients With Atherosclerosis. Stroke, 2004, 35, e369-72.	1.0	32
243	Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3498-3503.	3.3	666
244	A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics, 2004, 65, 267-277.	1.0	738
245	Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics, 2004, 5, 109-114.	0.7	67
246	Coercion and informed consent in research involving prisoners. Comprehensive Psychiatry, 2004, 45, 1-9.	1.5	105
247	Concordance between the CVLT and the WMS-III word lists test. Archives of Clinical Neuropsychology, 2004, 19, 319-324.	0.3	13
248	Cognitive and Psychiatric Aspects of Huntington Disease Contribute to Functional Capacity. Journal of Nervous and Mental Disease, 2004, 192, 72-74.	0.5	58
249	Retrograde Amnesia in Dementia: Comparison of HIV-Associated Dementia, Alzheimer's Disease, and Huntington's Disease Neuropsychology, 2004, 18, 692-699.	1.0	47
250	fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. American Journal of Neuroradiology, 2004, 25, 1715-21.	1.2	183
251	Neuropsychological functioning pretreatment and posttreatment in an inpatient eating disorders program. International Journal of Eating Disorders, 2003, 33, 64-70.	2.1	61
252	Cognitive impairment in anorexia nervosa is not due to depressed mood. International Journal of Eating Disorders, 2003, 33, 351-355.	2.1	28

#	Article	IF	CITATIONS
253	The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biological Psychiatry, 2003, 53, 422-430.	0.7	138
254	A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS Study. American Journal of Human Genetics, 2003, 73, 682-687.	2.6	148
255	Factor Analysis of the Frontal Systems Behavior Scale (FrSBe). Assessment, 2003, 10, 79-85.	1.9	179
256	Neuropsychological studies in geriatric psychiatry. Current Opinion in Psychiatry, 2003, 16, 643-648.	3.1	1
257	Capacity to Provide Informed Consent for Participation in Schizophrenia and HIV Research. American Journal of Psychiatry, 2002, 159, 1201-1207.	4.0	175
258	Neuropsychological characteristics of patients in a hospital-based eating disorder program. Annals of Clinical Psychiatry, 2002, 14, 203-7.	0.6	17
259	Neuropsychiatric aspects of Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 310-314.	0.9	387
260	Ecological Validity of Neuropsychological and Personality Measures of Executive Functions. Clinical Neuropsychologist, 2001, 15, 314-323.	1.5	62
261	Detection of mild cognitive deficits in Parkinson's disease patients with the WAIS–R NI. Journal of the International Neuropsychological Society, 2001, 7, 535-543.	1.2	16
262	Effects of Depression on Working Memory in Presymptomatic Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 342-346.	0.9	39
263	Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders. Movement Disorders, 2001, 16, 1098-1104.	2.2	42
264	Clinical markers of early disease in persons near onset of Huntington's disease. Neurology, 2001, 57, 658-662.	1.5	197
265	Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry, 2001, 13, 129-34.	0.6	53
266	Bioavailable testosterone as a correlate of cognition, psychological status, quality of life, and sexual function in aging males: implications for testosterone replacement therapy. Annals of Clinical Psychiatry, 2001, 13, 75-80.	0.6	17
267	Neurobehaviors and psychotic symptoms in Alzheimer's disease. Journal of the International Neuropsychological Society, 2000, 6, 815-820.	1.2	57
268	Traumatic Brain Injury in School-Age Children Academic and Social Outcome. Journal of School Psychology, 2000, 38, 571-587.	1.5	46
269	Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology, 2000, 54, 1965-1971.	1.5	252
270	Estimation of Premorbid Intelligence: The Word Accentuation Test - Buenos Aires Version. Journal of Clinical and Experimental Neuropsychology, 2000, 22, 677-685.	0.8	47

#	Article	IF	CITATIONS
271	Cognitive Deficits and Psychopathology in Institutionalized versus Community-Dwelling Elderly Schizophrenia Patients. Journal of Geriatric Psychiatry and Neurology, 1999, 12, 11-15.	1.2	36
272	Generalized Cognitive Deficits in Schizophrenia. Archives of General Psychiatry, 1999, 56, 749.	13.8	390
273	A Test of Odor Fluency in Patients with Alzheimer's and Huntington's Disease. Journal of Clinical and Experimental Neuropsychology, 1999, 21, 341-351.	0.8	51
274	The disparate effects of Alzheimer's disease and Huntington's disease on semantic memory Neuropsychology, 1999, 13, 381-388.	1.0	75
275	Odor detection, learning, and memory in Huntington's disease. Journal of the International Neuropsychological Society, 1999, 5, 609-615.	1.2	61
276	Schizoaffective Disorder. Journal of Clinical Psychiatry, 1999, 60, 874-882.	1.1	101
277	Is There a "Subcortical―Profile of Attentional Dysfunction? A Comparison of Patients with Huntington's and Parkinson's Diseases on a Global-Local Focused Attention Task. Journal of Clinical and Experimental Neuropsychology, 1998, 20, 873-884.	0.8	25
278	Apathy Is Not Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 314-319.	0.9	554
279	Neuropsychiatric Assessment of Patients With Hyperkinetic and Hypokinetic Movement Disorders. Archives of Neurology, 1998, 55, 1313.	4.9	128
280	Is it possible to be schizophrenic yet neuropsychologically normal?. Neuropsychology, 1997, 11, 437-446.	1.0	436
281	Nondementia Nonpraecox Dementia Praecox?: Late-Onset Schizophrenia. American Journal of Geriatric Psychiatry, 1997, 5, 302-317.	0.6	113
282	Impairment of the semantic network in schizophrenia. Psychiatry Research, 1996, 63, 109-121.	1.7	140
283	Dissociations within nondeclarative memory in Huntington's disease Neuropsychology, 1996, 10, 538-548.	1.0	152
284	Electrophysiological insights into the nature of the semantic deficit in Alzheimer's disease. Neuropsychologia, 1996, 34, 827-841.	0.7	47
285	Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study. Psychopharmacology, 1996, 123, 307-314.	1.5	29
286	Unified Huntington's disease rating scale: Reliability and consistency. Movement Disorders, 1996, 11, 136-142.	2.2	1,890
287	Frontal Behavioral Syndromes in Cortical and Subcortical Dementia. Assessment, 1996, 3, 327-337.	1.9	55
288	The biasing effect of verbal labels on memory for ambiguous figures in patients with progressive dementia. Journal of the International Neuropsychological Society, 1995, 1, 271-280.	1.2	4

#	Article	IF	CITATIONS
289	Sensory- and memory-mediated olfactory dysfunction in Huntington's disease. Journal of the International Neuropsychological Society, 1995, 1, 281-290.	1.2	85
290	Discrimination of cortical from subcortical dementias on the basis of memory and problem-solving tests. Journal of Clinical Psychology, 1995, 51, 48-58.	1.0	59
291	The nature of learning and memory impairments in schizophrenia. Journal of the International Neuropsychological Society, 1995, 1, 88-99.	1.2	256
292	Visual attention and perception in patients with Huntington's disease: Comparisons with other subcortical and cortical dementias. Journal of Clinical and Experimental Neuropsychology, 1995, 17, 654-667.	0.8	36
293	The effects of perceived versus enacted social support on the discriminative cue function of spouses for pain behaviors. Pain, 1995, 60, 103-110.	2.0	58
294	A comparison of category and letter fluency in Alzheimer's disease and Huntington's disease Neuropsychology, 1994, 8, 25-30.	1.0	251
295	Neuropsychological impairment in Tardive dyskinesia Neuropsychology, 1994, 8, 227-241.	1.0	10
296	The neuropsychology of aging. Current Opinion in Psychiatry, 1994, 7, 347-353.	3.1	4
297	Utility of a modified version of the wisconsin card sorting test in the detection of dementia of the alzheimer type. Neuropsychology, Development and Cognition Section D: the Clinical Neuropsychologist, 1993, 7, 161-170.	1.4	44
298	An Assessment of the Semantic Network in Patients with Alzheimer's Disease. Journal of Cognitive Neuroscience, 1993, 5, 254-261.	1.1	183
299	Prism adaptation in Alzheimer's and Huntington's disease Neuropsychology, 1993, 7, 73-81.	1.0	48
300	Counseling Psychology and Neuropsychology. Counseling Psychologist, 1992, 20, 626-634.	0.8	2
301	Differentiating dementia from "pseudodementia" early in the clinical course: Utility of neuropsychological tests Neuropsychology, 1992, 6, 13-21.	1.0	34